Comparative Pharmacology
Head-to-head clinical analysis: FORTAZ versus VANTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAZ versus VANTIN.
FORTAZ vs VANTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
Cefpodoxime proxetil is a semisynthetic third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
100-200 mg orally twice daily for 10-14 days for community-acquired pneumonia; 100 mg orally twice daily for 5-7 days for acute exacerbations of chronic bronchitis; 100 mg orally twice daily for 10 days for uncomplicated skin and skin structure infections; 100 mg orally twice daily for 3-7 days for uncomplicated urinary tract infections; 200 mg orally twice daily for 10 days for complicated urinary tract infections.
None Documented
None Documented
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
The terminal elimination half-life in adults with normal renal function is about 2.2-2.8 hours. In children, it is approximately 1.5-2 hours. Prolonged half-life in renal impairment (up to 9-10 hours in severe impairment) requires dose adjustment.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Approximately 80-90% of cefpodoxime is excreted unchanged in the urine within 24 hours, mainly by glomerular filtration and tubular secretion. A small fraction is eliminated via bile and feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic